Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematological and musculoskeletal disorders with high unmet medical need. Its lead product candidate, KER-050, targets low blood cell counts in myelodysplastic syndromes and myelofibrosis, while KER-047 and KER-012 are being developed for the treatment of anemia and disorders associated with bone loss, respectively.
Frequently asked questions
Is Keros Therapeutics, Inc. (KROS) stock halal to invest in?
As of , KROS is not Shariah-compliant and is therefore not considered a halal investment. This assessment is based on the data available in Keros Therapeutics, Inc.'s most recent financial reports.
Does Keros Therapeutics, Inc. have any interest income?
No, Keros Therapeutics, Inc. has not reported any interest income. According to the company's latest annual
report for the fiscal year ending Dec 31, 2025, Keros Therapeutics, Inc. reported total revenue
of 244061000, with no separate interest income disclosed. However,
it's worth noting that some companies may report interest income as part of their revenue. For a detailed
breakdown of all interest income and revenue segments, please refer to the full Shariah compliance
report available in the Zoya app.
What guidelines are used to determine if Keros Therapeutics, Inc. stock is Shariah-compliant?
We use the guidelines set by the Accounting and Auditing Organization for Islamic Financial Institutions
(AAOIFI) to assess Shariah compliance. AAOIFI is a leading international organization that establishes
standards for Islamic finance. Their guidelines help determine if a company's business activities and
financial structure align with Islamic principles. These standards are widely respected in the Islamic
finance industry and provide a consistent framework for evaluating the Shariah compliance of stocks and
other financial instruments. AAOIFI's Shariah board includes renowned scholars such as Sheikh Muhammad
Taqi Usmani, Sheikh Mohamed Ali Elgari, Sheikh Abdullah AlManea, Sheikh Nizam Yaquby, and Dr. Aznan Hassan.
How often is Keros Therapeutics, Inc. stock reviewed for Shariah compliance?
The Shariah compliance status of Keros Therapeutics, Inc. stock is reviewed on a regular basis, with a minimum
frequency of once per quarter. However, if there are any significant changes or major developments
in the company's operations that may impact its compliance, an immediate review will be conducted to
ensure ongoing adherence to Shariah principles.
How can I stay updated on Keros Therapeutics, Inc.'s compliance status?
To stay informed, we recommend regularly checking Zoya for updates. You can also enable alerts within
the Zoya app to receive notifications whenever there is a change in the Shariah compliance of KROS,
or any other stocks you are monitoring. This is particularly useful as Shariah compliance can fluctuate
due to changes in a company's financial ratios or business activities.
Are dividends from Keros Therapeutics, Inc. stock considered halal?
No, dividends from KROS are not considered halal because the stock is currently not
Shariah-compliant. When a stock is non-compliant, any dividends received from it are considered
impermissible income and should be donated to charity as a form of purification. To learn more about
the purification process and how to handle impermissible income, read
our comprehensive guide.
Do I need to pay Zakat on my Keros Therapeutics, Inc. shares?
If you hold Keros Therapeutics, Inc. stock as an investment, through an Employee Stock Ownership
Plan (ESOP), stock options, restricted stock units (RSUs), or any other form of stock ownership, and
meet the Nisab threshold, you may be required to pay Zakat on it. The calculation of Zakat on investments
can be complex and depends on various factors. To help make this easy, we've created a free
Zakat calculator for stocks. For a more
seamless experience, use the Zoya mobile app, where you can link your brokerage account to
automatically import holdings.
Community posts
Related stocks
See how Keros Therapeutics, Inc. compares with its peers:
